Summary: There has been remarkable progress during the past decade in understanding of how genetic variations in drug metabolizing enzymes and transporters contribute to observed variation in drug responsiveness. Among drug transporters, the organic anion transporting polypeptide (OATP) class of transporters have proven to be remarkably important to the cellular uptake disposition of a variety of clinically important drugs, particularly in organs such as the intestine and liver; we now know that altered OATP activity may confer reduced efficacy and potentially increased risk of drug-related toxicity. OATP1B1 and OATP1B3 are widely recognized liver-specific members of the family known to modulate the hepatocellular uptake of drugs from the portal vein and thereby modulate systemic exposure and hepatic substrate drug extraction. On the other hand, OATP2B1 and OATP1A2 are expressed on the apical membrane of intestinal enterocytes and though to affect absorption of its drug substrates. Accordingly, genetic variations in these OATP transporters have clinically relevant functional consequences for drug absorption, distribution and excretion, as well as pharmacodynamics response in terms of drug efficacy and toxicity. This article addresses the present evidence of relevance to genetic variations in OATP1B1, OATP1B3, OATP2B1, and OATP1A2 in terms of drug response, efficacy and optimal therapeutics.
Introduction
Adverse drug reactions (ADRs), defined as the negative and adverse consequences associated with the use of a prescribed medicine, and thought to affect 26% of hospitalized patients. 1, 2) A major cause of ADRs relates to inter-patient differences in drug responsiveness, resulting in unpredictable drug disposition and pharmacological effect, thereby hampering the delivery of optimal drug therapy and dosing regimen. 3, 4) Interindividual differences in drug response can arise from a variety of factors including environmental, genetic, comorbidities, as well as determinants of drug disposition (absorption, distribution, metabolism and excretion).
Personalized medicine and pharmacogenomics represents important fields that seek to understand the molecular determinants of interindividual variability in drug response and utilizes individual genetic makeup in combination with clinical variables when choosing appropriate drug therapy and dosages. 5) In recognizing the importance of pharmacogenetics, the FDA has now incorporated genetic information to drug labels for over 100 drugs. 6) In the past decade, a number of single nucleotide polymorphisms (SNPs) have been identified in cytochrome P450 isozymes (CYPs) shown to predict drug disposition and clinical response. 7) While much focus has been on CYP enzymes, there has been growing appreciation for drug transporters expressed at plasma membranes of various tissues in determining the disposition and excretion of a wide range of xenobiotics. 8) Transport proteins can be subdivided into two categories, efflux transporters which pump substrates out of cells while uptake transporters facilitates the influx of substrates into cells (Fig. 1) . There are several families of uptake transporters responsible for the cellular uptake of a large range of drugs from blood across the plasma membrane. 9) In particular, the family of organic anion transporting polypeptides (OATPs, SLC gene family SLC21/ SLCO), expressed in organs such as the intestine, liver and kidney has important clinical implications to extent of drug absorption, elimination and tissue distribution. 9) There is emerging evidence to linking changes in OATP transport function to efficacy and safety of drugs. 10) Furthermore, functional genetic variation in SLCO genes encoding OATPs may contribute to variability in drug disposition and response. 11) Thus, a better understanding of the impact of SNPs in OATPs will be essential for delivering optimal drug therapy. The current review summarizes the effect of SNPs in OATPs, specifically OATP1B1, OATP1B3, OATP2B1 and OATP1A2, to the disposition and responses of their drug substrates.
OATPs
Currently, the human OATP family consists of 11 members and genes encoding these transporters are classified as the SLCO. 12) OATP1B1, OATP1B3 and OATP2B1 are expressed on the basolateral membrane of hepatocyte and responsible for facilitating the hepatocellular uptake of its substrates from the portal circulation. 13, 14) While OATP1B1 and OATP1B3 are expressed exclusively in the liver, OATP2B1 appears to be more ubiquitously expressed, including the brush-border membrane of intestinal cells, facilitating the absorption of its substrates. 15) Conversely, although OATP1A2 was the first OATP to be identified in the liver, its expression is predominantly at the level of the blood brain barrier and to a lesser extent, intestine. 16) OATPs have demonstrated broad substrate specificity for transporting a variety of endogenous substances including bile acids, hormone conjugates, as well bilirubin, and drug substrates such as rifampicin, statins, fexofenadine and methotrexate. 17, 18) 
OATP1B1
The liver-specific OATP1B1 expressed on the sinusoidal membrane is responsible for the hepatic uptake of statins, some antidiabetic drugs as well as many chemotherapeutic agents. 17, 19) A detailed list of substrates can be found in Table 1 . Of note, OAPT1B1 has been the most extensively studied OATP, likely related to functional polymorphisms known to be associated with the SLCO1B1 gene. Not surprisingly, considerable attention has been given to delineating SNPs or haplotypes that result in functional consequences such as altered expression, localization and functional activity.
Genetic variations of OATP1B1: in vitro data: In 2001, our group was the first to identify and functionally characterize polymorphisms in SLCO1B1. 20) It should be noted that in 2001, this transporter was known as OATP-C, as well as OATP2 or SLC21A6. Subsequently, the transporter field adopted a standardized nomenclature system, and since then, this transporter has been named OATP1B1 (SLCO1B1). We identified a total of 14 non-synonymous SNPs in the coding region from European Americans and African Americans, in addition to the three nonconservative polymorphisms which are now widely cited, including the c.388A>G, c.455G>A, c.721G>A variants. We created the list of the variant SLCO1B1 alleles based on haplotype analysis. 17 alleles were defined and designated as SLCO1B1*1 (a, b, c) to SLCO1B1*14, where SLCO1B1*1a represents wildtype allele. Functional analysis of the defined variants in vitro demonstrated that several variants confer reduced uptake of used substrates estradiol-17¢-glucuronide, estrone-3-sulfate, and rifampicin (*2, c.217T>C; *3, c.245T>C and c.467A>G; *5, c.512T>C; *6, c.1058T>C; *9, c.1463G>C; *12, c.217T>C and c.467A>G; and *13, c.245T>C and c.467A>G), suggesting that a subset of these variants may account for interindividual variation in drug disposition. Interestingly, many variants associated with altered (Color online) Summary of drug transporters expressed at the human intestinal epithelia, hepatocytes, and kidney proximal tubule epithelia affecting uptake and excretion of substrates BCRP, breast cancer resistance protein; BSEP, bile salt export pump; MATE, multidrug and toxin extrusion; MDR, multi-drug resistance protein; MRP, multi-drug resistance-associated protein; OAT, organic anion transporter; OATP, organic anion transporting polypeptide; OCT, organic cation transporter; PEPT, peptide transporter.
Clinical Relevance of OATP SNPstransport function produce amino-acid changes within the fifth extracellular loop or the transmembrane-spanning domain. In addition, we showed that a number of variants affected cell surface membrane expression of OATP1B1 (*2, *3, *5, *6 and *9). Consistent with the decreased membrane expression, the c.512C>T SNP affected the maximum transport velocity rather than the substrate affinity of transport kinetics. 20, 21) More recently, Michalski et al. analyzed 81 human liver samples and defined SLCO1B1*18 as a naturally occurring mutation in the gene. 22) However, the functional consequence of this variant requires further assessment.
The cholesterol lowering class of statin drugs exerts its pharmacological effect by targeting the HMG-CoA-reductase enzyme in the liver; thus, the effect of genetic variations on the transport-mediated hepatocellular uptake of statins has been extensively investigated. SLCO1B1*1c, *2, *3, *5, *6, *9, *12 and *13 alleles all appeared to reduce OATP1B1-mediated uptake of rosuvastatin as compared to the SLCO1B1*1a protein. 23) Of those variants identified, the c.512T>C SNP has also been associated with reduced transport activity of atorvastatin, 21) cerivastatin, 21) pravastatin 21) as well as the active metabolite of antihyperlipidemic drug ezetimibe. 24) Beyond lipid lowering medications, this variant also affects transport of a number of other substrates including the metabolite of irinotecan SN-38, 25) rifampicin, 26) and astrasentan. 27) Another commonly studied variant in vitro is the c.388A>G (SLCO1B1*1b) SNP, however, its in vitro effects on OATP1B1 transport appear to be controversial. While some studies found decreased activity, 20, 24, 26) others found increased activity or no alteration in transport activity, depending on the substrate and expression system used in the transport experiment. 28, 29) However, of more importance is the fact that the c.512T>C and c.388A>G SNP can be in linkage disequilibrium and result in four functionally distinct haplotypes. The haplotypes were classified as follows: c.388A/c.521T combination is designated as *1a; c.388G/c.521T combination is designated as *1b; c.388A/c.521C combination is designated as *5; and c.388G/c.521C combination is designated as *15.
28) Interestingly, the activity of SLCO1B1*15 variant was reduced by over 70% as compared to SLCO1B1*1a for transport of estradiol-17¢-D-glucuronide in vitro. 29) Similarly, uptake of pravastatin, atorvastatin, cerivastatin, rosuvastatin, and SN-38 was found to be reduced by the *15 haplotype. 21, 23, 25) Additionally, a SNP located in the promoter region of SLCO1B1 (g.¹11187G>A), was found to be in linkage disequilibrium with c.521T>C and c.388A>G. 30) Although this SNP was found in the promoter, no expression difference was observed in liver samples of a Japanese population.
31) The haplotype containing g.¹11187G>A promoter variant in combination with C.512T>C and c.388A>G variants was designated as SLCO1B1*17. SLCO1B1 SNPs and haplotype definitions are summarized in Table 2 and Table 3 , respectively.
Genetic variations of OATP1B1: in vivo data: Given the extent of evidence supporting the role of OATP1B1 to the hepatic uptake of wide range of substrates in vitro, a number of groups studied the impact of genetic variation in SLCO1B1 on substrate drug pharmacokinetics and response in humans. Perhaps the most extensively studied class of drugs in relation to OATP1B1 is the statins. Significant interindividual variability exists in plasma concentrations pravastatin despite the fact that its extent of metabolism is small. 32) Given that pravastatin is a recognized substrate of OATP1B1 in vitro, 33) loss of OATP1B1 function was predicted to result in limited entry of pravastatin in hepatocytes, leading to higher accumulation in the plasma. Nishizato et al. first described the association of SLCO1B1 genotype with pravastatin pharmacokinetics.
34) Individuals carrying the SLCO1B1*15 allele had significantly reduced clearance compared to SLCO1B1*1a individuals. Accordingly, the area under the plasma concentration curve (AUC) of pravastatin of SLCO1B1*15/*15 individuals was increased almost two-fold compared to SLCO1B1*1a carriers. These findings were replicated in 41 healthy subjects, whereby the AUC was 106% higher in individuals heterozygous for c.512T>C compared to SLCO1B1*1a individuals. 30) Moreover, SLCO1B1*15 and *17 heterozygous carriers resulted in highest increase in AUC, by 1.9 and 2.3 fold, respectively. 30) In a later study, Igel et al. confirmed that the effect of c.512T>C on pravastatin pharmacokinetics can also be seen at steady state following multiple dosing. 35) Collectively, these data in humans undoubtedly supports the role of SLCO1B1 c.512T>C SNP to altered pravastatin disposition. The same trend was observed for atorvastatin, and rosuvastatin, where the AUC of significantly increased by 2.4 and 1.7 fold, respectively, in presence of the SLCO1B1 c.521T>C SNP. 36, 37) However, no significant difference was observed on the AUC of lipophilic simvastatin lactone, but 3.2 fold higher for the acid form, suggesting that hydrophilicity of the statin may determine the extent of SLCO1B1*5 impact on hepatic uptake of statins. 38) Although the effect of SLCO1B1*5 genotype on statin disposition is in line with in vitro findings, analyzing the effect of c.388A>G (*1b) SNP on OATP1B1-mediated transport of pravastatin has been conflicting. Individuals who are carriers of SLCO1B1*1b had lower plasma concentrations compared to wild type *1a carriers, suggesting an enhanced hepatic entry of pravastatin. 39, 40) This is in contrast to the observed reduced activity of the genotype in vitro in addition to exerting opposite pharmacokinetic effects on pravastatin than SLCO1B1*5. Conversely, the inverse effect of SLCO1B1*1b genotype on pharmacokinetics was not observed for rosuvastatin, suggesting that the effect may be substrate-dependent. 41) Interestingly, pravastatin AUC in two children with familial hypercholesterolemia harboring the SLCO1B1 g.¹11187G>A variant allele was 70% lower than pediatric patients wild type for this allele. 42) Taken together, SLCO1B1 genotype undoubtedly affects statin disposition, where decreased hepatocellular uptake results in enhanced plasma exposure and vice versa (Fig. 2) . More importantly, this may be accompanied by reduced lipid-lowering efficacy due to insufficient hepatic concentration needed to inhibit HMG-CoA-reductase.
As such, the clinical relevance of SLCO1B1 genetic variants has been most extensively studied in context of statin therapy ( Table 4 ). The hepatic cholesterol synthesis was assessed in healthy volunteers administered with multiple-dosing 40 mg pravastatin by measurement of plasma cholesterol and lathosterol concentrations. 43) Indeed, the AUC and maximum concentration reached (Cmax) was 2.3 fold higher in variant carriers (SLCO1B1*15 and *17) compared to control group, corresponding with lowered lipid-lowering effectiveness. Similarly, SLCO1B1*1b and *5 genotype were associated with pravastatin's ability to inhibit HMG-CoA-reductase. 44) Conversely, a prospective study in 8 healthy volunteers found no association of lipid-lowering response with SLCO1B1*5, *15 or *17 genotype following 40 mg daily administration of pravastatin for 3 weeks despite a considerable higher plasma exposure of pravastatin. 35) In a small subset of Japanese patient population, SLCO1B1*5 genotype resulted in reduced lipid-lowering efficacy when compared to wild type carriers prescribed with simvastatin, atorvastatin, or pravastatin. 45) Nevertheless, the clinical relevance of the association of SLCO1B1 genotype with statin efficacy remains to be better characterized in a large patient cohort.
Although statins are generally well tolerated, statins can result in unexpected muscle toxicity ranging from mild myalgia to the life-threatening rhabdomyolysis. It is thought that high statin dose and plasma exposure of statins may be a significant contributing factor to risk of statin-related muscle toxicity. 46) As noted earlier, available evidence demonstrates that plasma exposure of nearly all statins is increased in individuals carrying loss-of-function SLCO1B1 polymorphisms due to reduced hepatocellular uptake, particularly the SLCO1B1*5 allele. Thus, it would be plausible that the SLCO1B1*5 SNP increases risk of statin myopathy in patients carrying this allele. Indeed, the most convincing data to date comes from a recent genome-wide association study (GWAS) that identified a variant in SLCO1B1 in complete linkage disequilibrium with the SLCO1B1*5 allele to be the single most important predictor of simvastatin-induced myopathy risk in 85 patients with myopathy compared to 90 matched control subjects (SEARCH trial), whom were prescribed with high-dose 80 mg simvastatin. In that study, the odds ratio for myopathy-risk owing to SLCO1B1*5 was not additive and found to be 4.5 for heterozygous carriers and 16.9 for homozygous carriers. 47) These results was replicated in 10,000 patients prescribed with 40 mg simvastatin in the Heart Protection Study, demonstrating a myopathy odds ratio of 2.6 for each copy of the SLCO1B1*5 allele. The association of SLCO1B1 genotype with the lipid-lowering effects of simvastatin, although modest, was also confirmed. The reduction in LDL cholesterol by 40 mg simvastatin was 1.25% less for possessing per copy of SLCO1B1*5 allele. The authors concluded that these trends on toxicity and response will likely translate to other statins, given that myopathy risk is a class effect and the observed elevated exposure of other statins in presence of the SLCO1B1*5 allele. Indeed, in a study where 500 subjects were randomized to atorvastatin, simvastatin or pravastatin to study statin efficacy and toxicity, SLCO1B1*5 SNP was shown as a predictor of ADRs manifested as discontinuation of the statin, myalgia, or creatinine kinase elevation 3-times above baseline. 48) Moreover, SLCO1B1*5 allele was recently found to predispose to statin intolerance, defined as dose adjustment or statin switching in a large population of 4196 type 2 diabetes patients and thus, these individuals would be predicted to be at risk for reduced lipid-lowering effects. 49) In contrast, the association of SLCO1B1*5 with myopathy was replicated for simvastatin but not atorvastatin in a subsequent GWAS study. 50) Nevertheless, these data provide sufficient evidence to indicate that SNPs in SLCO1B1 alter pharmacokinetics, pharmacodynamics and contribute to statin-induced ADRs. Taken together, the evidence suggests that high dose statins should be used with caution if not avoided in patients possessing the SLCO1B1*5 SNP. Thus, genotyping for OATP1B1 polymorphisms may form a basis for tailored statin dosing in order to obtain optimal cholesterol lowering effects while minimizing risk of statin-induced myopathy.
Aside from statins, SLCO1B1 polymorphisms have also shown to influence the pharmacokinetics of numerous clinically important drugs ( Table 4) .
51) The cholesterol-lowering drug ezetimibe, lowering sterols through a different mechanism than statins, was demonstrated to be a substrate of OATP1B1 and OATP2B1; uptake of ezetimibe into cells was reduced in presence of SLCO1B1*1b and *5 variants. 24) In vivo, a gene-dose decrease in AUC of ezetimibe was observed for SLCO1B1*1b individuals and decreased fecal excretion of ezetimibe for both SLCO1B1*1b, *5 and *15 variant carriers following administration of 20 mg ezetimibe to 35 healthy volunteers. 24) Thus, OATP1B1 may be a contributor of interindividual variability in ezetimibe pharmacokinetics; however, no lipid-lowering response association was observed in that study.
Similarly, the SLCO1B1*5 genotype has been associated with a 3-fold increase in repaglinide, an antidiabetic medication exposure in 56 healthy volunteers. 52) These results were replicated in a subsequent healthy volunteer study where SLCO1B1*5 genotype resulted in increased repaglinide AUC while SLCO1B1*1b genotype corresponded to a 30% decrease in AUC, owing to decreased and increased hepatic uptake of the drug, respectively. 53, 54) In line with these pharmacokinetic differences, blood glucose response to repaglinide tended to be higher in individuals with SLCO1B1*5 genotype and reduced for individuals with SLCO1B1*1b genotype.
55) The effect of SLCO1B1 genotype on repaglinide pharmacokinetics and therapeutic response in patients with diabetes remains to be studied. On the other hand, the effect of OATP1B1 on nateglinide appears to be conflicting. While SLCO1B1*5 was associated with increased nateglinide AUC in a Chinese population, the same trend could not be replicated in a large cohort of Caucasians. 55, 56) Thus, OATP1B1 may not significantly contribute to variability in hepatic uptake and systemic exposure of nateglinide. The thiazolidinedione antidiabetic rosiglitazone has been identified as a possible OATP1B1 inhibitor in vitro; however, the SLCO1B1*5 genotype had no effect on its pharmacokinetics. 57) Methotrexate clearance was found to be significantly reduced in the subset of patients with the SLCO1B1*5 genotype in a recent GWAS study with 434 children diagnosed with acute lymphoblastic leukemia. 58) In addition, alleles in SLCO1B1 that confer lower plasma exposure were associated with elevated risk of gastrointestinal (GI) toxicity, indicating that higher hepatic exposure may predispose greater GI exposure of methotrexate. Exposure to the antibiotic rifampicin has been associated with OATP1B1 genotype and more recently, the SLCO1B1*15 haplotype was identified as a contributor to occurrence of rifampicin-induced liver toxicity in a Chinese population of 273 patients. 59) Moreover, the immunosuppressant mycophenolic acid plasma exposure was recently found to be higher in SLCO1B1*5 variant carriers, although the influence was more pronounced with SLCO1B3 genetic variants. 60, 61) Subsequently, a report showed a link between SLCO1B1*5 genotype and mycophenolic acid response in 218 renal transplant patients, indicating that impaired OATP1B1 activity resulted in a lower incidence of mycophenolic acid-related ADRs including gastrointestinal disturbance, hematotoxicity and infections.
62) The authors concluded that SLCO1B1*5 genotype may provide a protective role for mycophenolic acid induced toxicity.
Additionally, pharmacokinetics of fexofenadine, tacrolimus, irinotecan, lopinavir, olmersartan, torsemide, and enalpril has all been associated with SLCO1B1 genotype.
6368) The effect of SLCO1B1*5 allele on these substrates appears to be consistent in that impaired hepatic uptake confer enhanced plasma exposure while the SLCO1B1*1b allele results in the opposite trend (Fig. 2) . Taken together, genetic variations in the OATP1B1 transporter appears to be a major contributing factor that explain interindividual variability in drug disposition and response. Genotyping specific variants in SLCO1B1, in particular SLCO1B1*5 and *15, may prove useful in predicting therapeutic efficacy and safety profile of its substrates on an individual patient basis.
OATP1B3
Compared to the wide array of data on the functional consequences of OATP1B1 genetic variations, data on genetic variation for other members of the OATP family are limited.
Nevertheless, OATP1B3 is the second liver-specific OATP family member that shares 80% amino acid sequence and not surprisingly, share similar and overlapping substrate specificity ( Table 1) .
Genetic variations of OATP1B3: in vitro data: A number of genetic variations have been described previously in the SLCO1B3 gene encoding OATP1B3 ( Table 2 ). In 2001, Iida et al. identified the nonsynonymous variation SLCO1B3 c.334T>G as well as variations in the noncoding region of SLCO1B3. 69) However, the functional consequences of these variations were not characterized in that study. Subsequently, Letschert et al. identified additional variants in this gene in addition to characterizing the consequences of these polymorphisms in terms of functional activity, expression and localization. 70) The variants found in the Caucasian population were SLCO1B3 c.334T>G, c.699G>A, and c.1563G>T with frequencies of 74%, 71% and 1.9%, respectively. The consequences of these variants were assessed in HEK293 and MDCKII cells, where SLCO1B3 c.334T>G and c.699G>A did not lead to alteration in protein expression or transport activity for 6 different substrates: bromosulfophthalein, estradiol-17¢-glucuronide, taurocholate, choleocystokinin-8, deyhydroepiandrosterone-3-sulfate, and estrone-3-sulfate. The lack of functional difference of these two variants compared to wild type was confirmed in a subsequent study in Xenopus laevis oocytes using chemotherapeutic agent paclitaxel as the substrate. 71) Interestingly, among these variants, only c.699G>A resulted in decreased uptake of choleocystokinin-8 and rosuvastatin in a recent study studying transport in HeLa cells. 70) Furthermore, the variants c.332T>G and c.699G>A confer attenuated uptake of two recently reported substrates of OATP1B3, testosterone and mycophenolic acid. 60, 72, 73) The discrepancy in the functional consequence of the aforementioned polymorphisms might be in part explained by the use of diverse expression systems and substrates used for transport analysis.
More recently, in a population subjects from diverse ethnic backgrounds, 6 nonsynonymous polymorphisms in the coding region of SLCO1B3 were identified and characterized for functional activity and expression: c.334T>G, c.699G>A, c.439A>G, c.767G>C, c.1559A>C, and c.1679T>C, of which the latter four were novel variants unreported previously. 74) Functional analysis of these variants revealed that choleocystokinin-8 transport was significantly attenuated for c.699G>A, c.1559A>C, and c.1679T>C variants compared to wild type. The haplotype c.332T>G and c.699G>A resulted in a more pronounced decrease in choleocystokinin-8 transport than analysis of c.699G>A alone. Additionally, the variants c.1559A>C and c.1679T>C were associated with reduced total and cell surface expression compared to wild type, responsible for the impaired magnitude of transport function. The finding that Vmax of transport kinetics was reduced for these variants while the Km remained unaltered substantiates this.
Genetic variations of OATP1B3: in vivo data: The relevance of SLCO1B3 genetic polymorphisms on the pharmacokinetics and response for various drug substrates has been evaluated ( Table 5 ). The impact of SLCO1B3 SNPs c.334T>G and c.699G>A on paclitaxel pharmacokinetics in cancer patients of 6 ethnic groups was found to have no association with paclitaxel clearance or exposure. 75) Another chemotherapeutic agent, docetaxel, was also identified to be a substrate of OATP1B3. Similar to paclitaxel, no alteration on docetaxel pharmacokinetics has been associated with OATP1B3 polymorphisms found in the coding region to date. 76, 77) These negative findings could be partly explained by the compensation by other transporter proteins with overlapping substrate specificity. Interestingly, patients harboring a novel intron SNP (intron 12, IVS12-5676A>G) had significantly higher docetaxel AUC (1.6-fold) while the clearance was attenuated by the same extent, compared to wild type patients. 78) Importantly, patients carrying this variant were at a higher risk of docetaxelinduced adverse events in the form of leukopenia and neutropenia. Moreover, one report showed that healthy volunteers heterozygous for the IVS12-5657A>G intronic SNP had increased telmisartan AUC compared to wild type allele carriers. 79) No dramatic difference were found with olmesartan pharmacokinetics and OATP1B3 genetic variation following extensive sequencing of SLCO1B3.
80)
The SNPs c.334T>G and c.699G>A were found to be associated with pharmacokinetics of mycophenolic acid, whereby exposure among variant carriers were significantly higher compared to wild type renal transplant patients. 81) However, more recently, Picard et al. found the opposite trend in renal transplant patients.
60) The authors concluded that this change in exposure is in line with reduced enterohepatic recirculation of mycophenolic acid owing to impaired hepatic uptake in patients carrying variant genotype. The c.334T>G SNP was also recently associated with increased imatinib clearance in 34 Japanese CML patients. 82) Indeed, further studies are needed to delineate the impact of individual OATP1B3 polymorphisms on other drug substrates.
OATP2B1
Unlike OATP1B1 and OATP1B3, in addition to its expression on the basolateral membrane of hepatocytes, OATP2B1 is also expressed on the apical membrane of enterocytes, where it may modulate the absorption of its substrates from the intestinal lumen. 83) OATP2B1 is also expressed in the lung, ovary, placenta and muscle. Although its substrate specificity appears to be similar to OATP1B1 and OATP1B3, the spectrum of substrates is narrower ( Table 1) . 15) Interestingly, OATP2B1 exhibits pH-dependent transport with increased transport activity at acidic pH. 84) Although the mechanism for this pH-dependency is unclear, physiological pH of intestinal lumen is weakly acidic indicating that its transport and expression at enterocytes may have of clinical importance.
Genetic variations of OATP2B1: in vitro and in vivo data: Compared to the abundance of reports for genetic variations in OATP1B1 and OATP1B3, far less in vitro and in vivo OATP2B1 polymorphism data are available ( Table 2) . Thus far, only a few variants have been described in the SLCO2B1 gene. One of the first variants described is SLCO2B1*3, a nonsynonymous polymorphism of c.1457C>T, which demonstrated decreased transport activity in vitro. 15) Compared to SLCO2B1*1 wild type expression in transport systems, uptake of substrate estrone-3-sulfate was significantly reduced by 42% after normalizing for OATP2B1 protein expression level. 28) Functional characterization of SLCO2B1*3 transport kinetics in vitro revealed decreased Vmax while affinity remained unchanged and the intrinsic transport activity of SLCO2B1*3 was less than half of SLCO2B1*1. The effect of this allele on fexofenadine pharmacokinetics was evaluated following 60 mg oral administration in a Japanese population. 85) A gene-dose effect on AUCs was observed, whereby the AUCs for variant SLCO2B1*3 individuals were significantly reduced. Additionally, Cmax reached was lower in variant individuals while time to Cmax and clearance was unchanged, indicating that the c.1457C>T genotype likely confer altered intestinal absorption. Similarly, the same trend was observed for the beta-blocker celiprolol, whereby the wild type c.1457C>T individuals had the highest plasma concentration amongst the genotype groups. 86) However, a report demonstrated that c.1457C>T variant carriers exhibited higher plasma concentrations of S-fexofenadine, indicating enhanced transport activity of c.1457C>T compared to wild type. 87) Thus, these conflicting findings warrant additional studies with other substrates to evaluate the in vivo effect of the SLCO2B1*3 allele.
Another described variant in SLCO2B1 is c.935G>A, resulted in reduced transport of the leukotriene receptor antagonist montelukast in vitro in addition to reduced plasma concentrations in patients. 88) In fact, individuals carrying the variant allele exhibited lower improvement of symptoms and reduced therapeutic effect as compared to wild type patients. The effect of a number of SLCO2B1 variants evaluated, c.601G>A, c.935G>A, and c.1457C>T, showed no change on the OATP2B1 substrate aliskren, a direct renin inhibitor. 89) The SLCO2B1*2 (c.1175C>T) SNP was described to confer attenuated estrone-3-sulfate uptake compared to wild type in vitro. 28) Additionally, a recent report described that a polymorphism in the regulatory region of OATP2B1, g.¹282G>A, affects mRNA expression of OATP2B1 and thus could translate to interindividual differences in OATP2B1 protein expression at tissues. However, the clinical relevance of these SNPs requires further assessment in humans.
Overall, OATP2B1 may be an important determinant of intestinal absorption of its drug substrates (Table 5) , and genetic polymorphisms in this transporter could contribute to interindividual variability in drug disposition and efficacy. Importantly, since OATP2B1 is expressed in multiple tissues and organs, evaluation of efficacy and toxicity in such sites may shed light on additional mechanisms and relevance of this transporter. Interestingly, OATP2B1 expressed in the muscle was identified to transport statins, suggesting that muscle toxicity could be in part explained by OATP2B1-mediated accumulation of statins into muscle.
90)

OATP1A2
OATP1A2 has also been shown to localize at the apical membrane of intestinal epithelial cells, and may modulate uptake and absorption of its drug substrates. 91) However, the expression level of OATP1A2 in small intestinal cells has been controversial and subject to debate as its expression is very low or negligible compared to the abundantly expressed OATP2B1. 92) In addition, OATP1A2 protein expression has been found in the frontal cortex of brain tissue, which indicates that this transporter may have implications for brain penetration of drug substrates. 69, 93) Genetic variations of OATP1A2: in vitro and in vivo data: Iida et al. have identified several SNPs in the 5¤-regulatory region of the SLCO1A2 gene; however, their functional consequences on the OATP1A2 protein were not evaluated. 69) Subsequently, our group identified six exonic variations were identified in a population of mixed ethnic background, whereby three of the identified SNPs resulted in functional differences in uptake of substrates ( Table 2) . 94) Specifically, SLCO1A2 c.404A>T (SLCO1A2*6) and c.516A>C (SLCO1A2*3) decreased uptake of estrone-3-sulfate, deltorphin II and DPDPE while the c.559G>A (SLCO1A2*4) variant decreased uptake of deltorphin II only in a HeLa expression system. In another mixed ethnic population, 11 SNPs were identified and characterized in vitro. 95) In exon 1, the SLCO1A2 c.38T>C SNP (SLCO1A2*2) increased the uptake of estrone-3-sulfate and methotrexate. The novel variant identified in this study shown to have decreased transport function for substrate uptake was c.502C>T. However, functional consequences of six SNPs studied by both groups had discrepancies in transport function, likely due to use of different models for function analysis.
Thus far, only few have reported on the clinical consequence of genetic variations in SLCO1A2 ( Table 5) . It has been demonstrated that imatinib transport by OATP1A2 was abolished in presence of SLCO1A2 exonic genetic variants (SLCO1A2*3, *5 and *6). 96) Interestingly, analysis of OATP1A2 promoter polymorphisms and its association with imatinib pharmacokinetics revealed that SLCO1A2 g.¹366G>A, g.¹1105G>A and g.¹1032G>A variants resulted in decreased clearance of the drug in 34 chronic myeloid leukemia Japanese patients. 97) However, these results could not be replicated in subsequent studies. 96, 98) This discrepancy may be in part related to the small size and lack of statistical power in addition to variable disease populations. Therefore, future studies of sufficient sample size are needed to delineate the pharmacogenetic link between OATP1A2 polymorphisms to variation in substrate drug pharmacokinetics.
Conclusions
Unpredictable variation in drug exposure and efficacy has been a significant contributor to drug-related toxicities and inadequate therapeutic response. Therefore it is not surprising that a great deal of research has focused on identifying SNPs that impact pharmacokinetics, efficacy and toxicity. Carrier-medicated processes, broadly referred to as drug transporters that facilitate cellular drug entry and efflux are now widely appreciated as key determinants of observed variation in drug pharmacokinetics and efficacy. In fact, the International Transporter Consortium (ITC) has set been formed to better to better standardize and disseminate the role of drug transporters to drug response and toxicity.
11)
Moreover, there is a link between OATP function and human pharmacokinetics and ADRs for a number of drugs in clinical use. 99) Among the various drug transporters, it is clear that OATPs family of uptake transporters are clinically relevant. Moreover, genetic factors in OATP1B1, OATP1B3, OATP2B1 and OATP1A2 that alter transport function and expression significantly influence the pharmacokinetics of many widely prescribed drugs. Reduced function polymorphisms can often result in undesirable systemic exposure of the drugs; potentially leading to undesired prolongation of drug effect that can lead to drug accumulation and organ toxicity. Continued research on the role of OATPs using a combination of in vitro functional analysis as well as in vivo human studies in a variety of clinical settings will be essential to further our understanding of the molecular and genetic determinants of variation in drug responsiveness. In addition, integration of environmental and clinical variables such as demographics, existing disease states and drug-drug interactions in conjunction with genetic variables will likely aid in the delivery personalized medicine while at the same time and reducing the incidence of ADRs.
